Heart-Targeted LNP Development

Heart-Targeted LNP Development

We develop heart-targeted LNPs through cardiotropic lipid engineering and cardiac cell-targeting surface functionalization, providing end-to-end support from lipid design and synthesis to formulation, characterization, and delivery evaluation.

Heart-targeted LNPs are engineered to deliver nucleic acids and other payloads to cardiomyocytes, cardiac fibroblasts, and cardiac endothelial cells. Unlike conventional LNPs, which distribute 30–90% of the administered dose to the liver and spleen, heart-targeted formulations use cardiotropic ionizable lipids, tailored PEG-lipid architectures, or surface-displayed targeting ligands to redirect biodistribution toward the myocardium. These systems are being investigated for mRNA expression, gene silencing, genome editing, cardiac repair, and cardiovascular disease research.

BOC Sciences provides integrated targeted LNP development, covering cardiotropic lipid screening, targeting ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo cardiac evaluation. We support the development of customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with formulation and delivery-route strategies selected according to the intended cardiac target.

Schematic Diagram of Cardiac Tissue-Targeted Lipid NanoparticlesCardiac Tissue-Targeted Lipid Nanoparticle Illustration

BOC Sciences Heart-Targeted LNP Development Services

Our development services integrate lipid chemistry, cardiac cell-targeting surface engineering, nanoparticle formulation, and biological evaluation to address the delivery barriers specific to the heart. Projects can start with an existing LNP formulation, a candidate targeting ligand, or a defined cardiac-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.

Cardiac-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence cardiac-cell interactions, intracellular delivery, and tissue distribution.

  • Ionizable Lipid Selection: Compare lipid headgroups, ionization behavior, pKa, tail unsaturation, branching, and linker structures to identify candidates with cardiac-oriented tropism rather than default hepatic uptake. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Cholesterol Optimization: Adjust phospholipid identity, cholesterol content, and lipid ratios to maintain particle integrity, payload retention, and membrane interactions under cardiac-relevant conditions.
  • Structure-Performance Screening: Compare candidate lipid structures in human iPSC-derived cardiomyocyte and cardiac fibroblast models, using particle characteristics, cellular uptake, reporter expression, and heart-versus-liver expression readouts to identify formulation-dependent differences in cardiac delivery.

Cardiac Cell-Targeting Ligand Engineering and Surface Functionalization

We develop ligand-functionalized LNPs to improve interactions with selected cardiac cell populations. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.

  • Peptide Ligand Display: Evaluate cardiomyocyte-binding peptides, infarct-homing sequences, and cell-penetrating motifs, and incorporate them through suitable peptide-functionalized lipid nanoparticles designs.
  • Antibody and Aptamer Ligands: Explore antibody, antibody-fragment, and aptamer recognition components directed toward markers enriched on activated cardiac fibroblasts, injured endothelium, or other cardiac-associated cell populations, supported by our antibody-conjugated lipid nanoparticles and aptamer-conjugated lipid nanoparticles capabilities.
  • Conjugation and Surface Display: Optimize linker chemistry, lipid anchors, spacer design, coupling conditions, and ligand density through appropriate nanoparticle conjugation services, balancing surface accessibility against colloidal stability.

Payload-Compatible LNP Formulation and Delivery-Route Optimization

We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended cardiac-delivery application.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, mixing conditions, and formulation pH for different nucleic acid structures through customized lipid nanoparticle formulation.
  • PEG-Lipid and Ligand Balance: Adjust PEG-lipid content, ligand incorporation, and surface composition to balance circulation stability with cardiac-cell accessibility, supported by our LNP PEG-lipid optimization services.
  • Administration-Route Adaptation: Compare formulation requirements for systemic intravenous administration, intracoronary infusion, and intramyocardial injection, recognizing that each route presents different distribution, exposure, and cell-tropism conditions, and refine process parameters accordingly through LNP process optimization.

Physicochemical, Cardiac-Cell, and In Vivo Evaluation

We evaluate the physicochemical properties of candidate LNPs alongside cardiac-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, ligand density, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • Cardiac-Cell Uptake: Compare cellular association and internalization in human iPSC-derived cardiomyocytes, primary cardiac fibroblasts, and cardiac endothelial models using nanoparticle cellular uptake testing.
  • Functional Delivery: Evaluate reporter expression, target-gene knockdown, protein expression, or genome-editing outcomes according to the payload and research objective.
  • Tissue-Level Evaluation: Compare cardiac distribution, myocardial-region accumulation, target-cell localization, and hepatic and splenic off-target exposure through nanoparticle cellular and in vivo evaluation.

Heart-Targeting Strategies for Lipid Nanoparticles

Heart-targeted LNPs can be developed through intrinsic lipid engineering, cardiac-homing peptide display, injury-microenvironment-responsive design, or systematic formulation optimization. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies provide different options for developing heart-targeted delivery systems.

Ionizable Lipid-Engineered Cardiotropic LNPs

Cardiotropic LNPs can be developed by modifying ionizable lipid headgroups, hydrophobic tails, and linker structures to shift tissue distribution away from the liver and improve uptake by cardiac cells, which are known for their low endocytic activity. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.

  • Design Approach: Modify ionizable lipid headgroups, pKa, tail saturation, branching, asymmetry, and linker structures, and screen combinations with helper phospholipids, cholesterol, and PEG-lipids in cardiac-cell models.
  • Use Scenarios: Develop mRNA-LNPs for cardiac protein expression, base- or prime-editor component delivery for cardiomyocyte gene-editing research, and cardiac-associated gene modulation.

Research reference: 18:1 TAP10 LNPs identified through a human iPSC-derived cardiomyocyte screening platform, enabling cardiac mRNA delivery across multiple administration routes and adenine base-editor delivery with on-target correction in DMD patient-derived cardiomyocytes (PNAS, 2026).

Peptide-Functionalized Cardiac-Homing LNPs

Cardiac-homing peptides can be displayed on LNP surfaces to enhance binding to cardiomyocytes or to injured myocardium. BOC Sciences supports peptide synthesis, lipid-anchor conjugation, surface-density optimization, and LNP functionalization.

  • Design Approach: Conjugate cardiomyocyte-targeting peptide motifs, such as CMP-type binding sequences, to lipid anchors such as DSPE-PEG-MAL through thiol–maleimide chemistry, or apply AT1 receptor-recognition sequences enriched on the infarcted myocardium, while optimizing ligand density and spacer design.
  • Use Scenarios: Develop LNPs for cardiomyocyte-directed mRNA expression, infarct-region homing after systemic administration, and nucleic acid delivery to selected cardiac cell populations.

Research reference: AT1 receptor-targeted nanoparticles achieving selective delivery to the infarcted heart after intravenous injection (Biomaterials, 2011).

Microenvironment-Responsive Ischemic Myocardial-Targeted LNPs

The injured heart presents a dynamically changing microenvironment—inflammation, oxidative stress, and fibrosis—that can be exploited for targeted delivery. BOC Sciences supports responsive lipid design, injury-stage-informed formulation, and delivery evaluation.

  • Design Approach: Incorporate ROS-responsive lipid nanoparticles and pH-responsive lipid nanoparticles designs, or ligands recognizing injury-associated markers such as exposed collagen and activated-platelet markers, to align particle activation with the inflammatory, proliferative, or remodeling phase of injury.
  • Use Scenarios: Develop LNPs for ischemia-reperfusion and myocardial infarction models, where uptake timing and cell tropism shift across injury phases, and for anti-fibrotic or immunomodulatory payload delivery.

Research reference: High-resolution mapping showing that mRNA-LNP cell tropism in the injured heart shifts from myeloid cells at early time points toward fibroblasts, pericytes, and endothelial cells with delayed dosing (Journal of Molecular and Cellular Cardiology Plus, 2026); systemic LNPs accumulating functionally in the infarct area upon reperfusion (Journal of Controlled Release, 2022).

Formulation-Engineered Cardiac-Targeted LNPs

Cardiac delivery performance can be improved through systematic adjustment of helper lipid balance, cholesterol content, PEG-lipid architecture, and process parameters, particularly when combined with localized or catheter-based administration routes. BOC Sciences supports component-level optimization and route-adapted formulation development.

  • Design Approach: Adjust phospholipid identity and cholesterol content through LNP helper lipid optimization services and LNP cholesterol optimization services, then tune particle size, surface charge, and PEG density for the selected administration route.
  • Use Scenarios: Develop mRNA-LNPs intended for intracoronary infusion or intramyocardial injection, where widespread myocardial expression and remote-area coverage depend as much on route-compatible formulation as on lipid identity.

Research reference: Transcatheter intracoronary delivery of mRNA-LNPs achieving widespread myocardial expression—including cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts—and reducing infarct area with VEGF mRNA in an ischemia-reperfusion rabbit model (Journal of Controlled Release, 2025).

Which Heart-Targeting Strategy Fits Your LNP Project?

Share your payload and target-cell requirements. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.

Supported Payloads for Heart-Targeted LNPs

BOC Sciences develops heart-targeted LNPs for the payload classes most frequently used in cardiac delivery research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect heart-targeting design with payload-specific formulation requirements.

Payload TypeSupported Uses & Heart-Targeted LNP Development ConsiderationsRequest Information
Heart-Targeted LNP for mRNADesigned for reporter expression, paracrine-factor expression, and cardiomyocyte-directed protein expression research. Development focuses on mRNA integrity, encapsulation efficiency, cardiac-cell transfection, and heart-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Heart-Targeted LNP for siRNASuitable for gene-knockdown studies in cardiomyocyte and cardiac fibroblast models, including pathways involved in hypertrophy, remodeling, and metabolism. Development evaluates siRNA encapsulation, target silencing in cardiac cells, and selectivity against hepatic uptake, drawing on our lipid nanoparticles for siRNA delivery experience.Inquiry
Heart-Targeted LNP for miRNAApplicable to post-transcriptional regulation studies in cardiac remodeling and regeneration models. Development considers miRNA loading stability, target-cell uptake, and functional pathway readouts, supported by our lipid nanoparticles for miRNA delivery services.Inquiry
Heart-Targeted LNP for Cas9 mRNA and sgRNAApplicable to genome-editing research in cardiac models, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in cardiac cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
Heart-Targeted LNP for circRNA and saRNADesigned for payloads that require strong protection and sustained expression in cardiac tissue. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in cardiac-associated cell models, supported by our lipid nanoparticles for circRNA delivery platform.Inquiry
Heart-Targeted LNP for ASOSuitable for splice-modifying and knockdown oligonucleotide research in cardiac models, where oligonucleotide delivery to cardiomyocytes remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across cardiac cell populations, supported by our lipid nanoparticles for ASO delivery services.Inquiry
Heart-Targeted LNP for Protein and PeptideApplicable to enzymes, signaling proteins, and peptide payloads intended for cardiac-associated delivery research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience.Inquiry
Heart-Targeted LNP for Small MoleculeDesigned for hydrophobic, amphiphilic, or ionizable small molecules studied in cardiac injury, oxidative stress, and metabolic research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs.Inquiry
Heart-Targeted LNP for Fluorescent and Tracking LabelsSupports labeled particles used to map cardiac uptake, intracellular localization, and in vivo myocardial distribution trends, enabled by our fluorescent-labeled lipid nanoparticles capabilities.Inquiry
Heart-Targeted LNP for Custom PayloadDeveloped for unusual payloads, co-delivery systems, or early feasibility studies, including multi-payload cardiac formulations. We evaluate payload compatibility, loading sequence, heart-targeting modification route, particle stability, and delivery performance in the agreed cardiac cell models, supported by our lipid nanoparticles for co-delivery capabilities.Inquiry
Need a Heart-Targeted LNP for Your Specific Payload?

Tell us your payload, target cardiac cell population, and delivery goal, and BOC Sciences will propose a heart-targeting strategy that fits your project.

Our Heart-Targeted LNP Development Workflow

Projects can begin with an existing LNP formulation, a candidate cardiac-targeting ligand, or a defined myocardial delivery objective. We organize development into four practical stages, with formulation and biological evaluation used to guide each subsequent iteration.

Cardiac delivery project requirement discussion

1Define the Cardiac Target, Cell Population, and Payload

We review the payload class, intended cardiac region, target cell population, administration route, and desired biological readouts. Target populations may include cardiomyocytes, cardiac fibroblasts, endothelial cells, pericytes, and cardiac-associated immune cells. We also consider whether the project focuses on healthy myocardium, ischemic tissue, or post-injury remodeling. These inputs establish the initial formulation objectives, comparator groups, and evaluation plan.

Cardiac LNP lipid composition and targeting architecture selection

2Select Lipid Composition, Surface Design, and Delivery Route

We propose candidate ionizable lipids, helper lipid and cholesterol balances, PEG-lipid architectures, and surface modification options. The targeting layer is selected according to the intended mechanism, such as intrinsic lipid-mediated distribution, cardiac-homing peptide display, or injury-responsive chemical structures. Administration routes, including intravenous, intracoronary, and intramyocardial delivery, are evaluated according to the target region and expected tissue exposure. Lipid ratios and component combinations are screened to establish suitable candidate formulations.

Heart-targeted LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidates are prepared using controlled mixing conditions and compared for particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload retention. During formulation optimization, we adjust lipid ratios, ligand input, PEG-lipid content, mixing conditions, purification, and buffer exchange. Where appropriate, nanoparticle intracellular localization detection can be used to investigate cellular distribution and intracellular trafficking. Candidate formulations are advanced according to predefined particle and payload performance criteria.

Cardiac cellular and in vivo LNP delivery evaluation

4Evaluate Cardiac Distribution and Functional Payload Delivery

Selected candidates are evaluated in cardiac cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, protein production, or gene knockdown. Nanoparticle in vivo imaging services can support the investigation of heart-associated distribution, while nanoparticle in vivo distribution analysis can compare myocardial accumulation with hepatic, splenic, and other organ exposure. Findings are summarized as comparative datasets with documented formulation tradeoffs and suggested next experiments.

What Challenges Do We Solve in Heart-Targeted LNP Development?

A heart-targeted LNP may show favorable particle characteristics yet still produce insufficient myocardial exposure or uneven delivery across cardiac cell populations. We investigate lipid composition, surface properties, administration route, and intracellular trafficking together to identify the factors limiting cardiac delivery.

✔ Hepatic Accumulation and Limited Cardiac Delivery of LNPs

Conventional LNPs frequently accumulate in the liver after systemic administration because of interactions with plasma proteins and hepatic uptake pathways. ApoE adsorption and receptor-mediated uptake are particularly relevant to this distribution pattern. We compare ionizable lipid structures, PEG-lipid content, helper lipid composition, and particle surface properties to investigate ways of improving myocardial exposure. Heart-to-liver delivery ratios are evaluated alongside absolute tissue-associated payload signals, rather than relying only on total organ fluorescence.

✔ Restricted Vascular Access and Limited Myocardial Penetration of LNPs

The cardiac microvascular endothelium, capillary architecture, and myocardial extracellular matrix can restrict nanoparticle access to deeper tissue regions. LNPs may remain within vascular compartments or show uneven distribution around local administration sites. We investigate particle size, surface charge, PEG-lipid architecture, ligand accessibility, and administration route to improve tissue exposure. Comparative imaging and tissue analysis help determine whether formulation changes improve penetration beyond the vascular or injection-site region.

✔ Uneven LNP Delivery Across Cardiac Cell Populations

Cardiomyocytes, fibroblasts, endothelial cells, pericytes, and immune cells can exhibit different uptake patterns. These patterns may also change after myocardial injury. For example, a 2026 study mapping LNP uptake after ischemia-reperfusion injury found that myeloid cells were prominent recipients during the early inflammatory phase, while fibroblast, pericyte, and endothelial cell uptake became more evident following delayed administration. We use cell-population-aware readouts, imaging, and flow cytometry to identify which cardiac cells receive the payload and whether the distribution matches the intended research objective.

✔ Limited LNP Retention and Intracellular Endosomal Escape

After local administration, LNPs may disperse rapidly from the myocardial injection site, reducing local payload exposure. Following cellular uptake, a second limitation may arise when payloads remain trapped in endosomal compartments rather than reaching their functional intracellular destination. We investigate lipid composition, acid-responsive components, particle surface properties, and local retention strategies to distinguish tissue-level loss from post-uptake delivery limitations. Where suitable, ECM-associated LNP architectures can be explored to improve local retention, while LNP endosomal escape evaluation helps identify intracellular release limitations.

Are You Facing Challenges in Heart-Targeted LNP Development?

Tell us about your current lipid composition, payload, administration route, and cardiac delivery results. BOC Sciences can help investigate the formulation and biological factors limiting performance and establish a focused optimization plan.

Applications of Heart-Targeted LNPs

Heart-targeted LNPs offer opportunities for nucleic acid and other payload delivery in myocardial injury, cardiomyopathy, cardiac fibrosis, and tissue repair research. Different applications require different target cells and biological endpoints. BOC Sciences supports customized formulation development for these research areas, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.

01

Myocardial Infarction and Ischemia-Reperfusion Injury Research

  • Myocardial Repair: Develop mRNA-LNPs carrying VEGF-related factors to investigate vascular and lymphatic remodeling, tissue repair, and recovery after myocardial injury. A 2025 study reported that VEGF-C mRNA-loaded LNPs promoted lymphangiogenesis and reduced inflammatory and fibrosis-associated responses after myocardial infarction (Biomaterials, 2025).
  • Inflammatory Response Modulation: Explore siRNA or mRNA payloads targeting inflammatory signaling and immune-cell functions in injured myocardium. Payload selection should consider the timing of administration because cardiac cell uptake patterns can change during the inflammatory and repair phases.
  • Myocardial Distribution: Compare systemic administration, intracoronary delivery, and direct myocardial injection according to the intended tissue exposure. A 2016 study demonstrated modified mRNA delivery to rat and pig myocardium using formulated lipidoid nanoparticles, including direct myocardial and intracoronary administration (Molecular Therapy, 2016).
02

Cardiomyopathy and Heart Failure Research

  • Cardiac Contractility Regulation: Explore siRNA or mRNA delivery targeting calcium-handling proteins and other regulators of cardiomyocyte function. ATP2A2, which encodes SERCA2A, has been investigated as a cardiac siRNA target in a cardiotropic LNP study.
  • Cardiomyocyte Protein Expression: Develop mRNA-LNPs for transient expression of selected cardiac functional proteins and investigate their effects on myocardial cell behavior and contractility-related readouts.
  • Delivery Strategy Selection: Compare systemic and local administration approaches according to the intended myocardial distribution. The ApoE-dependent cardiotropic LNP study provides a research reference for systemic cardiac RNA delivery, although its reported biodistribution depended on experimentally altered ApoE conditions.
03

Cardiac Fibrosis and Adverse Remodeling Research

  • Fibrosis-Associated Gene Regulation: Develop siRNA-LNPs targeting selected signaling pathways involved in fibroblast activation, extracellular matrix remodeling, and inflammatory responses.
  • Macrophage-Associated Signaling: Investigate RNA delivery to cardiac immune cells to study macrophage polarization and the regulation of inflammatory pathways after myocardial injury.
  • Localized RNA Retention: Explore ECM-associated LNP composites to improve payload retention in myocardial tissue. A 2025 study reported an ECM-LNP system carrying EGFR siRNA that reduced cardiac fibrosis and promoted M2 macrophage polarization in a mouse myocardial infarction model (Materials Today Bio, 2025).
04

Cardiac Regeneration and Vascular Repair Research

  • Angiogenesis: Develop mRNA-LNPs carrying selected vascular growth factors to investigate endothelial responses, microvascular recovery, and tissue perfusion after ischemic injury.
  • Lymphatic Regeneration: Explore VEGF-C mRNA delivery to investigate lymphatic network formation, myocardial fluid balance, and inflammatory regulation after infarction.
  • Cellular Repair Mechanisms: Evaluate candidate mRNA or gene-modulating payloads in cardiomyocytes, endothelial cells, and other cardiac-associated cell populations. Delivery efficiency should be assessed together with cell-specific expression and tissue-level functional outcomes.
Develop a Heart-Targeted LNP for Your Research Application

Tell us your intended cardiovascular research application, target cardiac cell population, payload, and delivery requirements. BOC Sciences can help design, synthesize, formulate, and evaluate heart-targeted LNPs according to your project objectives.

Why Choose BOC Sciences for Heart-Targeted LNP Development?

Cardiotropic Lipid Chemistry Beyond Liver-Default Formulations

We connect ionizable lipid structure, helper lipid balance, cholesterol content, and PEG-lipid architecture with cardiac delivery outcomes. This structure-guided approach helps investigate formulation variables that may influence myocardial exposure rather than relying on conventional liver-oriented LNP compositions.

Multi-Layer Heart-Targeting Ligand Toolbox

Our development workflows cover cardiac-homing peptide synthesis, lipid-anchor conjugation, surface display, and ligand-density optimization. We evaluate targeting components according to their experimental evidence, target accessibility, and compatibility with the selected LNP composition.

Administration-Route-Informed Formulation Design

We consider intravenous, intracoronary, and intramyocardial administration when selecting lipid composition, surface architecture, and particle properties. Matching the formulation to the intended route helps address differences in circulation, myocardial exposure, tissue penetration, and local retention.

Integrated In Vitro and In Vivo Evaluation

Particle profiling, cardiac-cell uptake, functional payload readouts, and tissue-distribution studies are combined in one development program. This allows formulation changes to be interpreted against both cellular and myocardial delivery data, including off-target organ exposure.

End-to-End LNP Formulation and Process Optimization

From lipid selection and ligand synthesis to nanoparticle assembly, characterization, and delivery evaluation, the development chain is organized within one integrated plan. Parallel candidate comparisons help identify the formulation variables that require further optimization.

FAQs

How are lipid nanoparticles engineered for heart targeting?

Heart-targeted LNPs can be developed by modifying ionizable lipid structures, optimizing PEG-lipid composition, or introducing cardiac-homing ligands. These modifications influence protein adsorption, tissue distribution, cellular uptake, and intracellular payload release. Other approaches include acid-responsive lipid components and formulation-process optimization to improve myocardial delivery. The optimal design depends on the target cardiac cell population, payload characteristics, and administration route. BOC Sciences supports customized ionizable lipid screening, targeting ligand synthesis, surface functionalization, and LNP formulation to develop cardiac-directed delivery systems.

Cardiomyocyte delivery depends on several interconnected factors, including particle size, surface charge, lipid composition, PEG-lipid density, and interactions with circulating proteins. After systemic administration, hepatic accumulation can reduce the amount of LNPs reaching myocardial tissue. Vascular access, extracellular matrix barriers, cellular uptake, and endosomal escape further influence functional delivery. BOC Sciences evaluates these parameters through lipid composition screening, particle characterization, cardiomyocyte uptake studies, and tissue distribution analysis to identify formulation characteristics associated with improved cardiac delivery.

Yes. Heart-targeted LNPs can be designed for different payload classes, including mRNA, siRNA, plasmid DNA, microRNA, antisense oligonucleotides, and selected protein or small-molecule payloads. Applications include cardiac protein expression, gene silencing, genome-editing research, inflammatory pathway modulation, and myocardial repair studies. Each payload requires an appropriate loading strategy based on its molecular size, charge, structural stability, and intracellular destination. BOC Sciences provides payload-compatible LNP formulation, encapsulation optimization, and functional delivery evaluation for different cardiovascular research objectives.

Administration routes influence LNP circulation, cardiac exposure, tissue penetration, and local retention. Intravenous administration provides systemic exposure but may result in substantial hepatic accumulation. Intracoronary delivery introduces nanoparticles through the coronary circulation, while intramyocardial injection provides more localized exposure around the injection site. Each route presents different formulation and evaluation requirements. BOC Sciences considers the intended administration route when selecting lipid composition, particle properties, and surface modifications, helping researchers compare delivery strategies according to their target myocardial region and experimental objectives.

Evaluation combines physicochemical characterization, cardiac-cell uptake analysis, functional payload measurements, and tissue-level distribution studies. Particle size, polydispersity index, zeta potential, morphology, and encapsulation efficiency provide information about formulation properties. Cellular studies can compare uptake in cardiomyocytes, cardiac fibroblasts, and endothelial cells, while functional assays assess reporter expression, gene knockdown, or protein production. In vivo evaluation can examine myocardial accumulation, cardiac cell localization, and distribution in organs such as the liver and spleen. These complementary measurements help determine whether an LNP achieves meaningful cardiac delivery.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code